Heart failure & cardiomyopathies
Beta-Blocker Use and Outcomes in Patients with Heart Failure and Mildly Reduced and Preserved Ejection Fraction
Authors' conclusion
In this observational analysis of non-randomized BB treatment, there was no suggestion that BB use was associated with worse HF outcomes in HFmrEF/HFpEF, even after extensive adjustment for other prognostic variables.
Study context
- Population
- Patients with HFmrEF or HFpEF (mean left ventricular ejection fraction (LVEF) 56.8%; 79.1% HFpEF, LVEF ≥50%)
- Participants
- 16,951 patients4 trials
- Comparison
- Beta-blocker (BB) use vs no BB use
- BB usersn = 12,812
- Outcome
- CV death or heart failure (HF) hospitalization
Methodological detailsobservational, individual patient data pooled from I-Preserve, TOPCAT, PARAGON-HF and DELIVER
- Observational
- Individual patient data pooled from I-Preserve, TOPCAT, PARAGON-HF and DELIVER
Pooled result
As reported in the abstract
BB users vs Non-usersHazard ratio (95% CI)
Unadjusted
0.98(0.91–1.05)
Adjusted
0.81(0.74–0.88)
Further pooled results
| Outcome | BB users |
|---|---|
| BB dose and continuation · 2 yearsBisoprolol-equivalent dose | median 5.0 (IQR 2.5–5.0) mg |
| Continuation (survivors) at 2 years | 93.1% |
Primary outcome by history of MI, hypertension, or baseline heart rate <70 bpm (subgroups)
- Adjusted risk similar in BB users and non-users with or without these
Primary outcome by AF (subgroup)
- Better outcome with BB use in patients with AF vs without AF
- Interaction P = 0.02
Original publication
Beta-Blocker Use and Outcomes in Patients with Heart Failure and Mildly Reduced and Preserved Ejection Fraction. Eur J Heart Fail. Published 31 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →